Medicamen Biotech Limited (MEDICAMEQ) — Capital Reinvestment Ratio

Latest as of March 2022: 2.09x

Medicamen Biotech Limited (MEDICAMEQ) has a Capital Reinvestment Ratio of 2.09x as of March 2022, meaning it reinvests 2% of its operating cash flow (Rs41.09 Million) in capital expenditures (Rs86.08 Million). Check tangible net worth ratio of Medicamen Biotech Limited to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

2.09x
Capex / Operating Cash Flow

Operating Cash Flow

Rs41.09 Million
INR

Capital Expenditures

Rs86.08 Million
INR

Data as of

Mar 2022
Most recent filing

Medicamen Biotech Limited Capital Reinvestment Ratio (2006–2022)

This chart tracks Medicamen Biotech Limited's Capital Reinvestment Ratio across 13 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Medicamen Biotech Limited.

Annual Capital Reinvestment Ratio for Medicamen Biotech Limited (2006–2022)

Year-by-year Capital Reinvestment Ratio for Medicamen Biotech Limited from 2006 to 2022. See how much free cash does Medicamen Biotech Limited generate to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (INR) Capital Expenditures YoY Change
2022 2.09x Rs41.09 Million Rs86.08 Million ▲ +48.9%
2021 1.41x Rs127.72 Million Rs179.66 Million ▼ -52.1%
2020 2.94x Rs128.02 Million Rs376.11 Million ▼ -19.4%
2019 3.65x Rs43.01 Million Rs156.81 Million ▲ +464.6%
2017 0.65x Rs35.92 Million Rs23.20 Million ▲ +494.8%
2016 0.11x Rs62.06 Million Rs6.74 Million ▼ -43.1%
2014 0.19x Rs51.39 Million Rs9.80 Million ▼ -44.4%
2011 0.34x Rs113.52 Million Rs38.93 Million ▼ -89.3%
2010 3.20x Rs11.00 Million Rs35.20 Million ▲ +1210.1%
2009 0.24x Rs83.07 Million Rs20.29 Million ▼ -82.7%
2008 1.41x Rs22.70 Million Rs31.97 Million ▼ -92.8%
2007 19.44x Rs2.59 Million Rs50.30 Million ▲ +2501.1%
2006 0.75x Rs26.02 Million Rs19.45 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow